Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best affordable growth stocks to buy. In a report released on August 27, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), setting a price target of $750.00.

On August 26, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported that its Cemdisiran monotherapy, dosed subcutaneously every three months, met the “primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score.”

Management announced that the US regulatory submission for cemdisiran monotherapy is planned for Q1 2026, pending discussions with the FDA.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions. The company is advancing around 40 of its programs.

It has relied on two primary products to drive top-line growth in the past years: Dupixent and Eylea. Dupixent is an eczema treatment whose rights Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares with Sanofi. Eylea, which Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) comarkets with Bayer, treats wet age-related macular degeneration.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.